Diabetologia·1 OctComparative hepatic effectiveness of empagliflozin vs dapagliflozin among individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver diseaseCohort study of 265,098 peopleEmpagliflozinPaper